Category: JCN Newswire

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov 1, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd.  and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug

More

NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents

Toyota City, Japan, Oct 31, 2024 – (JCN Newswire via SeaPRwire.com) – Today, Toyota Motor Corporation (hereafter, Toyota) and Nippon Telegraph and Telephone Corporation (hereafter, NTT) have agreed to a joint initiative in the field of mobility and AI/telecommunications with

More

Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD)

TOKYO, Oct 31, 2024 – (JCN Newswire via SeaPRwire.com) –  Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference,

More